Literature DB >> 24429386

A safe-by-design approach to the development of gold nanoboxes as carriers for internalization into cancer cells.

Dania Movia1, Valerie Gerard2, Ciaran Manus Maguire3, Namrata Jain3, Alan P Bell4, Valeria Nicolosi5, Tiina O'Neill6, Dimitri Scholz6, Yurii Gun'ko2, Yuri Volkov7, Adriele Prina-Mello8.   

Abstract

Gold nanomaterials are currently raising a significant interest for human welfare in the field of clinical diagnosis, therapeutics for chronic pathologies, as well as of many other biomedical applications. In particular, gold nanomaterials are becoming a promising technology for developing novel approaches and treatments against widespread societal diseases such as cancer. In this study, we investigated the potential of proprietary gold nanoboxes (AuNBs) as carriers for their perspective translation into multifunctional, pre-clinical nano-enabled systems for personalized medicine approaches against lung cancer. A safe-by-design, tiered approach, with systematic tests conducted in the early phases on uncoated AuNBs and more focused testing on the coated, drug-loaded nanomaterial toward the end, was adopted. Our results showed that uncoated AuNBs could effectively penetrate into human lung adenocarcinoma (A549) cells when in simple (mono-cultures) or complex (co- and three-dimensional-cultures) in vitro microenvironments mimicking the alveolar region of human lungs. Uncoated AuNBs were biologically inert in A549 cells and demonstrated signs of biodegradability. Concurrently, preliminary data revealed that coated, drug-loaded AuNBs could efficiently deliver a chemotherapeutic agent to A549 cells, corroborating the hypothesis that AuNBs could be used in the future for the development of personalized nano-enabled systems for lung cancer treatment.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Gold nanoboxes; High content screening and He-ion microscopy; Lung cancer barrier; Safe-by-design; Three-dimensional culture; Tiered approach

Mesh:

Substances:

Year:  2014        PMID: 24429386     DOI: 10.1016/j.biomaterials.2013.12.057

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  6 in total

1.  Biophysical restriction of growth area using a monodispersed gold sphere nanobarrier prolongs the mitotic phase in HeLa cells.

Authors:  Dae-Woong Jung; Hyun-Joo Ro; Junmin Kim; Seung Il Kim; Gi-Ra Yi; Gaehang Lee; Sangmi Jun
Journal:  RSC Adv       Date:  2019-11-18       Impact factor: 4.036

2.  Diffusion Reflection Method for Early Detection of Oral Squamous Cell Carcinoma Specifically Targeted by Circulating Gold-Nanorods Bio-Conjugated to Anti-Epidermal Growth Factor Receptor.

Authors:  Dror Fixler; Abraham Hirshberg; Shiran Sudri; Hamootal Duadi; Florin Altman; Irit Allon; Ariel Ashkenazy; Ruchira Chakraborty; Ilya Novikov
Journal:  Int J Nanomedicine       Date:  2021-03-17

3.  Gold Nanoparticles-enabled Efficient Dual Delivery of Anticancer Therapeutics to HeLa Cells.

Authors:  Muhammad U Farooq; Valentyn Novosad; Elena A Rozhkova; Hussain Wali; Asghar Ali; Ahmed A Fateh; Purnima B Neogi; Arup Neogi; Zhiming Wang
Journal:  Sci Rep       Date:  2018-02-13       Impact factor: 4.996

Review 4.  Three-dimensional (3D) liver cell models - a tool for bridging the gap between animal studies and clinical trials when screening liver accumulation and toxicity of nanobiomaterials.

Authors:  Melissa Anne Tutty; Dania Movia; Adriele Prina-Mello
Journal:  Drug Deliv Transl Res       Date:  2022-05-04       Impact factor: 5.671

5.  Targeted polyethylene glycol gold nanoparticles for the treatment of pancreatic cancer: from synthesis to proof-of-concept in vitro studies.

Authors:  Jolanda Spadavecchia; Dania Movia; Caroline Moore; Ciaran Manus Maguire; Hanane Moustaoui; Sandra Casale; Yuri Volkov; Adriele Prina-Mello
Journal:  Int J Nanomedicine       Date:  2016-02-26

Review 6.  Characterisation of particles in solution - a perspective on light scattering and comparative technologies.

Authors:  Ciarán Manus Maguire; Matthias Rösslein; Peter Wick; Adriele Prina-Mello
Journal:  Sci Technol Adv Mater       Date:  2018-10-18       Impact factor: 8.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.